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Abstract 
The relative efficacy and harms of balloon kyphoplasty (BK) for treating vertebral 
compression fractures (VCF) are uncertain. We searched multiple electronic databases to 
March 2016 for randomised and quasi-randomised controlled trials comparing BK with 
control treatment (non-surgical management [NSM], percutaneous vertebroplasty [PV], 
KIVA®, vertebral body stenting, or other) in adults with VCF. Outcomes included back pain, 
back disability, quality of life (QoL), new VCF and adverse events (AE). One reviewer 
extracted data, a second checked accuracy, and two rated risk of bias (ROB). Mean 
differences and 95% confidence intervals were calculated using inverse-variance models. 
Risk ratios of new VCF and AE were calculated using Mantel-Haenszel models. Ten unique 
trials enrolled 1,837 participants (age range: 61-76 years, 74% female), all rated as having 
high or uncertain ROB. Versus NSM, BK was associated with greater reductions in pain, 
back-related disability, and better QoL (k=1 trial) that appeared to lessen over time, but were 
less than minimally clinically important differences. Risk of new VCF at 3 and 12 months 
was not significantly different (k=2 trials). Risk of any AE was increased at 1 month 
(RR=1.73 [1.36, 2.21]). There were no significant differences between BK and PV in back 
pain, back disability, QoL, risk of new VCF or any AE (k=1 to 3 trials). Limitations included 
lack of a BK versus sham comparison, availability of only one RCT of BK versus NSM, and 
lack of study blinding. Individuals with painful VCF experienced symptomatic improvement 
compared with baseline with all interventions. The clinical importance of the greater 
improvements with BK versus NSM is unclear, may be due to placebo effect, and may not 
counterbalance short-term AE risks. Outcomes appeared similar between BK and other 
surgical interventions. Well-conducted randomized trials comparing BK with sham would 
help resolve remaining uncertainty about the relative benefits and harms of BK. This article is 
protected by copyright. All rights reserved 
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Introduction 
In the United States, vertebral compression fractures (VCF) account for nearly half of 
the approximately 1.5 million osteoporotic fractures every year (1). VCF can cause acute and 
chronic pain, physical impairment and disability, adversely impact quality of life, and are 
associated with an increased risk of future vertebral and non-vertebral fractures (2).  
 Medical treatments of VCF may reduce pain (3), but many patients still experience 
severe and sometimes long-ODVWLQJ V\PSWRPV $OWHUQDWLYHO\ VHYHUDO ³YHUWHEUDO
DXJPHQWDWLRQ´SURFHGXUHVKDYHEHHQGHYHORSHGWRWUHat patients with symptomatic VCF. The 
simplest of these is percutaneous vertebroplasty (PV), in which bone cement is 
percutaneously injected inside the fractured vertebral body. Balloon kyphoplasty (BK) 
involves inflation of a balloon inside the fractured vertebral body and balloon removal before 
injection of bone cement. With vertebral body stenting (VBS), balloon inflation and removal 
is followed by insertion of an expandable scaffold before injection of bone cement (4). With 
KIVA®, a nesting, vertically oriented, cylindrical column is inserted over a coil into the 
fractured vertebral body before injection of bone cement (5).  
Vertebral augmentation procedures may reduce pain and back-related disability by 
restoring vertebral height and stabilizing fractured vertebrae, but risks may include cement 
leakage associated nerve-root injury, rarely symptomatic pulmonary embolism, and a 
possible increase in frequency of subsequent vertebral fractures attributable to procedure-
related alterations in spine biomechanics (6). Of approximately 300,000 inpatient vertebral 
augmentation procedures performed in the U.S. between 2005 and 2010, 73% were BK and 
27% were PV (7).  
Given that BK is the most commonly performed vertebral augmentation procedure, 
we undertook this systematic review to compare its efficacy, relative efficacy and harms 
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versus other treatments for VCF in middle-aged and older adults, including versus non-
surgical management (NSM), sham control, PV and other vertebral augmentation techniques.  
 
Methods 
Data sources 
We followed the PRISMA guidelines (8). We searched MEDLINE (from 1946), 
Cochrane Library, EMBASE, CINAHL, Web of Science, Clinicaltrials.gov, and the World 
Health Organization International Clinical Trials Registry Platform Search Portal databases to 
November 2014 using the title/abstract search terms: >³N\SKRSODVW\´$1'³UDQGRPL]HG´
25 ³FRQWUROOHG´ $1' 127 ³PDOLJQDQF\´ $1' 127 ³UHYLHZ´@ ZLWK QR ODQJXDJH
restriction. We updated this search in March 2016.  
Study selection and inclusion criteria 
We included randomised controlled trials (RCTs) and quasi-randomised trials that 
enrolled adults aged >40 years with non-traumatic vertebral fractures and compared BK 
versus any treatment for at least one validated measure of pain, disability, physical function, 
health-related quality of life, participant-reported treatment success, balance, falls, posture, 
bone mineral density (BMD), incident clinical or radiographic vertebral fractures, or adverse 
events (AE). Two reviewers independently examined titles, abstracts, and full articles for 
eligibility and resolved discrepancies by discussion and consensus.   
Data extraction and risk of bias assessment 
Two reviewers independently extracted data on study design, participant 
characteristics, intervention characteristics, outcomes and adverse events, and an additional 
reviewer checked accuracy.  
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Studies were evaluated for risk of bias using the Cochrane Collaboration Risk of Bias 
Tool (The Cochrane Collaboration, v5.1.0), with potential sources of bias including random 
sequence generation, allocation concealment, blinding of participants and study personnel, 
blinding of outcome assessments, and completeness of reported outcomes data (9). For each 
domain, risk of bias was rated as high, low or unclear by two independent investigators and 
agreed to in a consensus meeting. When there were multiple reports for a single study, 
information from all reports was used to rate risk of bias for each domain for that study. Risk 
of bias was summarized for individual studies as low (low risk of bias for all domains), 
unclear (unclear risk of bias for >1 domain) or high (high risk of bias for >1 domain). 
Data analysis 
 For continuous outcomes, mean differences (MD) and 95% confidence intervals (CI) 
were calculated using inverse-variance models. For dichotomous outcomes, risk ratios (RR) 
and 95%CI were calculated using Mantel-Haenszel models. Statistical heterogeneity was 
determined by the I2 statistic, applying random-effects models when I2 > 50% (9). When 
there were multiple reports of a single study, the most recent publication was used as the 
primary data source and the other reports were used to provide supplemental information.  
 
Results 
Literature search 
Together, the initial and updated database searches yielded 2,460 unique references. 
We excluded 2,406 during title and abstract review and 40 during full-text review, leaving 14 
reports of 10 unique studies that met eligibility criteria and were included for analysis (4, 5, 
10-21) [Figure 1]. Characteristics of included studies are described in Table 1.  
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Risk of bias 
 Among the 10 unique eligible studies, the most common source of bias was lack of 
blinding, followed by inadequate or uncertain concealment of treatment allocation, and 
incomplete reporting of outcomes [Table 2], though it was not possible to mask assessors of 
radiographic outcomes to the vertebral cement in participants assigned to BK or other 
vertebral augmentation procedures. No trials were rated as having low risk of bias, two were 
rated as having unclear risk of bias (5, 14, 22), and eight were rated as having high risk of 
bias (4, 10-13, 16-21).   
Kyphoplasty versus Placebo or Sham 
 We identified no eligible trials that compared BK versus a sham BK procedure. 
Kyphoplasty versus Non-surgical management 
Study characteristics 
 Five reports met eligibility criteria, four of which were duplicate publications from 
the FREE trial (10, 11, 17, 20), so that there were two unique trials. Both were rated as 
having high risk of bias. The FREE trial (n=300) used computer generated permuted block 
randomization, after which participants and study staff were unblinded. Follow-up was 24 
months. The Yi trial (n=200) stated that participants were randomized, but also that treatment 
assignment was blindly chosen by a single surgeon (21). Outcome assessors but not 
participants were blinded to treatment assignment and follow-up was 48 months [Table 2]. 
Patient characteristics 
In the FREE trial, mean age was 72.2 years, and 77% of participants were female (10, 
11, 17, 20). Qualifying vertebral fractures were <3 months old (mean 6 weeks) and most 
commonly located at the thoracolumbar junction. Vertebral fractures were attributed to 
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osteoporosis (approximately 40% of participants had a spine T-score of <-2.5) (10, 20). At 
baseline, participants reported severe back pain (mean visual analogue scale [VAS (23)] 
score 6.8), substantial back-related disability (mean Rolland-Morris Disability Questionnaire 
[RMDQ (24)]) score 17.5), and poor health-related quality of life (mean Short Form-36 
Physical Component Summary Scale [SF-36 PCS (25)] score 25.7 and mean EuroQol [EQ-
5D (26)] score 0.18). In Yi et al. (21), mean age was 61.3 years and 62% were female. 
Qualifying vertebral fractures were described as symptomatic. However, no data were 
reported on the age, location or number of vertebral fractures per participant, prevalence of 
osteoporosis, or participant baseline pain, disability, or quality of life.   
Outcome measures 
Back pain 
BK was associated with significantly more reduction in pain than NSM at all time 
points, though the relative difference between groups in improvement in VAS appeared to 
diminish over time: MD in decline from baseline at 30 days (-1.82 [-2.37, -1.27]; n= 264 
participants); at three months (-1.45 [-2.01, -0.89]; n=246]); at six months (-1.48 [-2.05, -
0.91]; n= 241); at 12 months (-0.84 [-1.42, -0.26]; n= 226); and at 24 months (-0.69 [-1.27, -
0.11]; n=200) [Supplementary Table 1]. 
Back-related disability 
BK was associated with significantly more reduction in RMDQ than NSM at 30 days 
(-4.20 [-5.54, -2.86]; n=255), three months (-3.69 [-5.10, -2.28]; n=225), six months (-3.05 [-
4.50, -1.60]; n=230) and 12 months (-2.90 [-4.37, -1.43]; n= 204), but not at 24 months (-1.43 
[-2.91, 0.05; n=193]). The relative reduction in disability after BK compared with NSM 
appeared to diminish with time [Supplementary Table 2]. 
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Quality of life 
BK was associated with significantly more improvement than NSM on SF-36 PCS at 
30 days (5.40 [3.14, 7.66]; n=261), three months (4.00 [1.67, 6.33]; n=241) and six months 
(3.30 [1.00, 5.60]; n=237), but not at 12 months (1.60 [-0.73, 3.93]; n=225) or 24 months 
(1.50 [-0.83, 3.83]; n=186) [Supplementary Table 3]. By comparison, BK was associated 
with significantly more improvement than NSM on the EQ-5D at all time points up to 24 
months. For both these outcomes, the difference between groups appeared to diminish over 
time [Supplementary Table 4]. 
Incident vertebral fractures 
There was no statistically significant difference between BK and NSM participants in 
risk of new-onset radiographic vertebral fractures occurring at one month (7.4% vs. 4.6%; 
risk ratio [RR]=1.59 (0.63, 4.00); events=18; n=300), three months (21.9% vs. 27.0%; 
RR=0.81 [0.51, 1.29]; events=54; n=223), 12 months (33.0% vs. 25.3%; RR=1.31 [0.85, 
2.02]; events=62; n=220), or 24 months (47.5% vs. 44.1%; RR=1.08 [0.81, 1.44]; events=101; 
n=220) [Supplementary Table 5]; or at 24 months in incident adjacent radiographic vertebral 
fractures (23.7% vs. 16.7%; RR=1.54 [0.89, 2.65]; events= 45, n=220) or incident clinical 
vertebral fractures (20.8% vs. 17.9%; RR=1.07 [0.69, 1.68]; events=58; n= 300) (10, 17, 20, 
21) [Supplementary Table 6].  
Adverse events  
The FREE study reported a significantly increased risk of any AE occurring within 
one month following BK compared with NSM (63.1% vs. 36.4%; RR=1.73 [1.36, 2.21]; 
events= 149; n= 300), with the most common AEs being back pain, new vertebral fracture, 
nausea or vomiting, and urinary tract infection (17). By comparison, there was no difference 
in risk of any AE within 24 months (89.9% vs. 88.7%; RR=1.01 [0.94, 1.10]; events= 268; n= 
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300) (10, 17, 20). There was no significant difference in risk of serious AE, either within one 
month (16.1% vs. 11.3%; RR=1.43 [0.80, 2.55]; events= 41; n= 300) or 24 months of the 
intervention (49.7% vs. 48.3%; RR=1.03 [0.82, 1.29]; events= 147; n= 300) (10, 17, 20) 
[Supplementary Table 7].  
Kyphoplasty versus Vertebroplasty  
Study characteristics 
 Six reports (12, 14, 15, 18, 19, 21) met eligibility criteria, including five unique RCTs, 
(n=857) and one quasi-randomized study (n=112) (13). All six trials were rated as having 
high risk of bias. Two trials were single-blinded (19, 21), two trials were unblinded (12, 18), 
and two trials had no blinding specified (13-15). Treatment allocation was performed by 
computerised block randomisation in two studies (12, 14, 15), assigned by the operating 
surgeon in two studies (13, 21), and was not specified in two studies (18, 19). Follow-up 
duration ranged from six to 60 months (14, 15) [Table 2].   
Patient characteristics 
Mean participant age was 71.6 years and about 75% were female. Qualifying VCF 
were acute (<6 weeks old) or subacute (6-12 weeks old) (12-15), with some studies requiring 
or reporting supportive findings on MRI (12, 13, 19, 21). Fractures were most commonly 
located near the thoracolumbar junction. Three studies limited participation to individuals 
who had failed several weeks of conservative therapy (13, 18, 19). Three studies were limited 
to or were mostly comprised of participants with osteopenia or osteoporosis (12, 18, 19).   At 
baseline, participants reported severe back pain (mean VAS range 7.6-8.1) (12-15, 19), 
substantial back-related disability (mean Oswestry Disability Index [ODI (27)] range 58-66%) 
(12, 13, 19), and fair to poor quality of life (mean SF-36 PCS and EQ-5D approximately 28 
and 0.42, respectively) (12).  
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Outcome measures 
Back pain 
In two RCTs, results favored BK over VP at 30 days VAS MD= -0.28 [-0.43, -0.13]; 
n=107, k=1 trial) (19) and favored VP over BK at 5 years (0.60 [0.09, 1.11]; n=100, k=1 trial) 
(14), but there were no statistically significant differences at other time points (12, 15, 19) 
[Figure 2]. In the quasi-randomised study, there were no statistically significant differences 
(p<0.05) in VAS scores between treatment groups at any follow-up time point, but there was 
a statistically significant difference between groups in change from baseline to two year 
follow-up (0.60 [0.22, 0.98]; n=86) that was small and not likely to have been clinically 
meaningful (13).  
Back-related disability  
In two RCTs (12, 19) and one quasi-randomized study (13), there was no statistically 
significant difference between treatments in improvement in ODI from baseline to any time 
points ranging between three months and two years [Supplementary Table 8].  
Quality of life 
There was no statistically significant difference between treatments in improvement in 
SF-36 PCS or EQ-5D at any time point (12)  [Supplementary Table 9 & 10].  
Incident vertebral fractures 
There was no statistically significant difference between BK and VP in risk of 
incident radiographic vertebral fractures occurring within three months of intervention 
(23.3% vs. 27.4%, RR=0.85 [0.58, 1.26], k=1) (12), 12 months (28.3% vs. 31.5%, RR=0.89 
[0.66, 1.19], k=2) (12, 19), or 24 months (49.1% vs. 57.7%, RR=0.85[0.66,1.09], k=1) (12). 
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Similarly, there was no significant difference in risk of incident adjacent radiographic 
vertebral fracture occurring up to 12 months [6.0% vs. 7.0%; RR=0.91 (0.39, 2.15); n=278; 
k=3] (14, 15, 18, 19), 24 months [16.0% vs. 14.0%; RR= 1.14 (0.45, 2.91); n=100; k=1] (14) 
or 60 months [16.0% vs. 14.0%; RR= 1.14 (0.45, 2.91); n=100; k=1] (14). There was no 
significant difference in risk of incident clinical vertebral fracture at one month (4.7% vs. 
8.9%; RR=0.53 [0.24, 1.15]; k=1) (12), or 12 months (16.3% vs. 22.9%; RR=0.77, 0.53, 1.11, 
k=2) (12, 18)  [Supplementary Table 11], or, in one quasi-randomized study, at two years 
(18.2% vs. 14.3%, RR=1.27 [0.48, 3.36], n=86) (13).  
Adverse events 
Only one study reported data on adverse events, and found no increased risk of 
serious AE at 30 days (26.2% vs. 27.4%, p=0.82) (12, 28). This trial reported the most 
common individual types of AEs within 30 days of surgery as procedural pain 6% for BK vs. 
5% for VP, back pain 7% for BK vs. 15% for VP, and new symptomatic fracture 5% for BK 
vs. 9% for VP. Within 2 years of surgery, there did not appear to be a significant difference 
between treatment groups in risk of falls, pneumonia, bronchitis, or urinary tract infection. 
Kyphoplasty versus Vertebral body stenting 
 One eligible trial (n=63, 100 treated levels) randomized participants to BK versus 
VBS, and reported only that there were no neurologic sequelae in the immediate post-
operative period (4) [Table 2]. This trial was rated as having high risk of bias for lack of 
blinding of outcome assessment. 
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Kyphoplasty versus KIVA  
Study characteristics 
Two eligible trials randomized participants to BK versus KIVA (5, 16). One trial was 
blinded to participants, investigators and outcome assessors and (5) was rated as having 
unclear risk of bias due to unclear allocation of treatment assignment, while the other was 
blinded only to participants, and then only until after the procedure was completed (16), and 
was therefore rated as having high risk of bias. Follow-up was 14 and 12 months, 
respectively [Table 2]. 
Patient characteristics  
 Mean participant age was 73.7 years and 72.8% were female. Qualifying vertebral 
fractures were acute or subacute, and, in the one study that reported location, most commonly 
around the thoracolumbar junction (16). One trial limited participation to individuals who had 
failed conservative treatment, and reported a mean spine T-score in the osteopenic range. At 
baseline, participants reported severe back pain (mean VAS 8.6) and considerable back-
related disability (mean ODI 63%) (16). 
Outcomes 
Back pain, Back-related disability, and Quality of life 
There was no difference between treatment groups in the proportion of participants 
with >5.5 points improvement in back pain (VAS) (43% for BK vs. 54% for KIVA; RR=0.80 
[0.58, 1.10] (5)), with >1.5 points improvement in back pain (VAS) (97.6% vs. 95.3% (16)), 
or with undefined ³improved´ SF-36 PCS (59% for BK vs. 51% for KIVA (5)). There also 
was no between-group difference in achievement of a composite endpoint requiring a 1.5 
point improvement in VAS, and absence of either a >10 point worsening in ODI or a device-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
15 
 
related AE (16), and no between-group difference in mean improvement from baseline in 
back pain (VAS) (5, 16), back-related disability (ODI) (5, 16), or quality of life (SF-36 PCS) 
(5, 16).  
Incident vertebral fractures 
There was no difference between BK and KIVA participants in risk of incident 
radiographic vertebral fractures (12.8% vs. 12.2%, p=0.91) or incident adjacent radiographic 
vertebral fractures (17.1% vs. 15.7%, p=0.64) (5).  
Adverse events 
There was no difference in serious adverse events between BK and KIVA participants 
through 12 months (34.6% vs. 28.6%; RR=1.21; 0.84, 1.75; events= 80; n= 253] (16). 
Individual types of AEs were reported only if judged by trial investigators to be procedure-
related, including three participants randomized to KIVA with herpes zoster, post-procedural 
pain, and pruritus, respectively, and four assigned to BK with an airway complication, back 
pain, ischemic stroke, and rash, respectively (16). 
Discussion  
  On average, individuals with painful VCF experienced statistically significant 
symptomatic improvement compared with baseline with all studied treatment interventions, 
including NSM. Though we found that BK was associated with improved pain, back-related 
disability and quality of life outcomes compared with NSM, these results were derived almost 
entirely from a single trial. Further, magnitude of improvement from baseline in these 
outcome measures after BK relative to NSM appeared to diminish over time, mean between 
group differences were smaller than previously reported minimally clinically important 
differences in a population of individuals being treated for chronic low back pain (29), raising 
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concerns about their clinical significance. Because we identified no eligible trials of BK 
versus sham BK, it also was not possible to determine to what extent the observed 
improvements of BK versus NSM were attributable to a placebo effect.  
 Compared with NSM, BK was not associated with a statistically significantly increased 
risk of incident VCF, though confidence intervals were wide and results could not exclude a 
clinically meaningful increase in risk. Further, compared with NSM, BK was associated with 
a near doubling in risk of any AE within 30 days of intervention. Based on the mean 
between-group differences in efficacy outcomes of uncertain clinical importance, an increase 
in early AE, and the high risk of bias of the largest eligible BK versus NSM trial, it is 
uncertain whether any benefits of BK versus NSM for treatment of VCF outweigh potential 
harms, both in the VCF population overall and within selected patient subgroups.  
 We found no significant difference between BK and either PV or KIVA in pain, back-
related disability, or quality of life outcomes, or in risk of incident VCF, or risk of any AE or 
serious AE. These results were limited by the lack of results reporting the proportion of 
participants in each treatment group that experienced a clinically important difference in each 
efficacy outcome, wide confidence intervals around the estimates for risk of incident VCF 
that could not exclude clinically important differences in fracture risk, and limited reporting 
of AE outcomes. The high risk of bias ratings of all the trials that compared BK versus PV 
further limits confidence in these findings.    
 Uncertainty about the benefits and harms of BK relative to NSM, sham BK, PV or 
other treatments is further complicated by uncertainty about the effect of PV. A prior 
systematic review found no statistically significant difference between PV and sham PV in 
mean change from baseline to 1 month in either pain or back-related disability (30), both 
overall and in two participant subgroups postulated to be more likely to benefit from PV--
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those with recent VCF (<6 weeks) or with severe baseline back pain (score on 0-10 scale >8). 
Further analysis suggested that compared with participants randomized to sham PV, those 
assigned to PV may have been slightly more likely to experience clinically meaningful 
improvements in pain at 1 month (reduction in pain score of >3: RR=1.3 [0.8, 1.9]; reduction 
in pain score of >30%: RR=1.3 [1.0, 1.8]). A more recent RCT of PV versus sham PV for 
treatment of acute, severely painful VCF reported that participants assigned PV were 
significantly more likely than those in the sham PV group to have a clinically meaningful 
reduction in pain score between baseline and follow-up time points through 6 months (31). It 
is uncertain whether the apparent differences in outcomes between the earlier and more 
recent PV versus sham PV trials are attributable to methodological differences, including the 
lack of numbing of the periosteum and the greater volume of bone cement used in the recent 
trial. Combined with the differences in participant characteristics and in the PV intervention 
groups between the recent PV versus sham PV trial and those in prior BK versus PV trials, it 
seems unwise to make indirect comparisons between these sets of studies to draw inferences 
about the unstudied comparison of BK versus sham BK.    
 The current review was limited by available evidence. Though ten unique trials met 
eligibility criteria, after considering the different BK treatment comparisons, outcome 
measures and time points, only relatively few participants provided information about the 
efficacy and safety of BK versus other interventions. Second, because all but two trials 
reported results for efficacy outcomes only as overall group means (5, 16), it was difficult to 
determine how many and which types of participants achieved clinically meaningful 
improvements with treatment. Third, AEs and incident vertebral fractures were rarely 
systematically reported and often were not reported at all, particularly for individual types of 
AEs. This hampered our ability to weigh the relative harms of BK against any potential 
benefits. Fourth, most trials were rated as having high risk of bias, most commonly due to 
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lack of blinding of participants and/or outcome assessors, and less often due to a lack of 
allocation concealment, both which could have led to overestimation of the true effect of 
interventions.. 
 In conclusion, we found that in middle-aged and older adults with VCF, based on only 
a single RCT, BK was associated with greater improvement in pain, disability and quality of 
life and an increase in risk of early AE compared with NSM. However, the magnitude of 
treatment differences may have been too small to be clinically meaningful, diminished over 
time, and likely was attributable at least in part to a placebo effect. Based on a small number 
of heterogeneous (and high risk of bias) studies, there was no difference in these outcomes 
between BK and either the PV or KIVA vertebral augmentation techniques. Risks of 
subsequent fracture were not statistically significantly different between BK and other 
treatments, but results could not rule out important differences. These remaining areas of 
uncertainty should be addressed by future trials that randomize participants with acute and 
subacute painful VCF to BK versus sham BK, PV or KIVA®, mask study participants, 
investigators and outcome assessors, follow participants for at least one year, include 
adequately powered responder analyses for efficacy outcomes (e.g. proportion achieving a 
clinically important improvement in back pain), systematically collect results for clinical and 
radiographic vertebral fracture and AE, and include a priori subgroup analyses for patient 
groups with characteristics suspected to modify the effects of treatment. 
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Figure Legends 
Figure 1.  
Study selection flow diagram. 
Figure 2. 
Mean changes in back pain scores from baseline at 1, 3, 6, 12 and >12 months in kyphoplasty 
versus percutaneous vertebroplasty study groups.  
Figure 3.  
Incident radiographic vertebral fractures at 3, 12, and >12 months (number of events through 
to time point) in kyphoplasty versus percutaneous vertebroplasty study groups. 
Figure 4. 
Incident adjacent radiographic vertebral fractures at >12 months (number of events through to 
time point) in kyphoplasty versus percutaneous vertebroplasty study groups. 
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Table 1. Study Characteristics        
Study  Blinding Follow-
up (mo) Centres Countries 
Partici
pants Randomisation Outcome Measures* Funding 
BK vs. NSM          
 Wardlaw 2009, 
Boonen 2011, 
Borgstrom 
2013, Van 
Meirhaeghe 
2013 (FREE 
Trial) 
Unblinded 24 Multiple 
Belgium, 
Germany, 
Sweden, 
Scotland 
300 Computer-generated permuted block  
SF-36 PCS*, EQ5D, VAS, analgesic use RMDQ, patient 
satisfaction, TUG test, new VCF, kyphosis angle, RAD, 
QALY, vertebral height, AE  
Medtronic 
Spine LLC 
   Yi 2014 
  
Single blind 
(outcome 
assessor) 
48 Single China 200 
Both stated 
³UDQGRPL]HG´DQG
³VXUJHRQ«EOLQGO\
FKRVH«WUHDWPHQW´ 
New VCF*, AE No disclosures 
BK vs. PV          
   Du 2006 Not specified 24 Single China 86 
Quasi-randomized 
(divided according to 
the surgeon) 
VAS, ODI, vertebral height, participant satisfaction, 
kyphotic angle, new VCF 
No 
disclosures 
   Liu 2010, 2015 
Single blind 
(radiology 
techs) 
60 Single Taiwan 100 Permuted block  
Vertebral height, kyphotic angle, VAS, new VCF 
  
University/ 
Hospital grant 
   Vogl 2013 Single blind (participants) 12 Multiple 
Germany, 
USA 77 
Stated only as 
³UDQGRPL]HG´ Cement leakage*, vertebral height, new VCF Soteira Inc.  
   Dohm 2014 
(KAVIAR 
Trial) 
Single blind 
(radiology 
techs) 
24 Single USA 404 
Computer generated 
dynamic 
minimisation 
New VCF*, SF-36 PCS, EQ-5D, ODI, VAS, kyphosis 
correction, AE 
Medtronic 
Spine LLC 
   Wang 2015 
Blinded 
(participants, 
radiologists) 
12 Single China 107 Stated only as ³UDQGRPL]HG´ 
VAS, ODI, cement leakage, vertebral height restoration 
rate, new VCF, AE 
No 
disclosures 
BK vs. VBS          
   Werner 2013 Unblinded Post-op Single Switzerland 100 Computer generated block 
Kyphotic angle*, cement leakage, material-related 
complications 
No 
disclosures 
BK vs. KIVA          
   Korovessis 2013 
Blinded 
(participants, 
investigators, 
outcome 
assessors) 
14 Single Greece 163 Stated only as ³UDQGRPL]HG´  
Cement leakage, vertebral height, kyphotic angle, VAS, 
SF-36, ODI 
No 
disclosures 
 Tutton 2015   
(KAST Trial) 
Single blind 
(participants 
only until after 
procedure) 
12 Multiple USA, EU 300 Computer generated block  
Composite (reduced VAS by 15mm on 100mm VAS, 
improved or <10 point worsening ODI, absence  of 
device-related SAE)*, VAS, ODI, new VCF 
Benvenue 
Medical, Inc 
AE= adverse event; BK= balloon kyphoplasty; EQ5D= EuroQol 5 dimensions; NSM= non-surgical management; ODI= Oswestry disability index; PV= percutaneous vertebroplasty;  
QALY= quality adjusted life year; RAD= restricted activity days; RMDQ= Rolland Morris Disability questionnaire; SAE= serious adverse event; SF-36 PCS= short form 36 physical  
component summary score; TUG= timed up and go; VAS= visual analogue scale; VBS= vertebral body stenting; VCF= vertebral compression fracture 
*Specified as primary outcome measure. 
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